Error in Figure 2B
In the Original Investigation titled “Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination,” which was published September 1, 2023, the second pair of bars in Figure 2B was inverted. The article was corrected online. (Source: JAMA Neurology)
Source: JAMA Neurology - November 13, 2023 Category: Neurology Source Type: research
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels
This cohort study evaluates amyloid-related tau spreading in apolipoprotein E ε4 carriers and amyloid positron emission tomography thresholds at which tau spreading may accelerate. (Source: JAMA Neurology)
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis
This cohort study investigates the timing of neuroaxonal pathology in individuals with multiple sclerosis who experience disability worsening. (Source: JAMA Neurology)
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia
This randomized clinical trial examines data for patients with Alzheimer dementia to determine whether brexpiprazole is an efficacious, safe, and well-tolerated treatment for agitation. (Source: JAMA Neurology)
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
APOE Genotype and Alzheimer Disease Risk by Age, Sex, and Ancestry
This genetic association study assesses associations between apolipoprotein E and Alzheimer disease risk across age, sex, race and ethnicity, and global population ancestry. (Source: JAMA Neurology)
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid- β
The apolipoprotein E (APOE) ε4 allele has long been recognized as the strongest genetic risk factor for sporadic Alzheimer disease (AD). Compared with APOE ε3/ε3 (the most common genotype), ε4 heterozygosity (ie, 1 ε4 allele) and ε4 homozygosity (ie, ε4/ε4) incur a 3- to 4-fold and 10- to 15-fold increased risk of deve loping AD, respectively. However, these risk estimates fluctuate considerably across studies, which may partly be attributable to differences in key demographic variables (eg, age, sex, race, and ethnicity). Furthermore, although 66% of individuals with biologically defined AD carry at least 1 APOE- ...
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease
The article by Lee et al reports a randomized clinical trial of brexpiprazole for the treatment of agitation in the context of aggression in people with Alzheimer disease (AD). The study is timely, since the treatment of agitation in this patient group remains a high treatment priority, and the options for pharmacological interventions are limited. (Source: JAMA Neurology)
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
Error in Figure 1
This article was corrected online. (Source: JAMA Neurology)
Source: JAMA Neurology - November 6, 2023 Category: Neurology Source Type: research
Amyloid PET and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
This nonrandomized controlled trial compares rates of inpatient hospitalizations and emergency department visits between Medicare beneficiaries with cognitive decline who participated in the Imaging Dementia –Evidence for Amyloid Scanning study vs Medicare beneficiaries who had not undergone amyloid positron emission tomography. (Source: JAMA Neurology)
Source: JAMA Neurology - November 1, 2023 Category: Neurology Source Type: research
JAMA Neurology
Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topi...
Source: JAMA Neurology - November 1, 2023 Category: Neurology Source Type: research
Antiplatelets Are Enough for Nondisabling Stokes
This Viewpoint argues, in keeping with current stroke management guidelines, that patients with mild, nondisabling strokes should not receive thrombolysis, even when presenting within the time window for treatment. (Source: JAMA Neurology)
Source: JAMA Neurology - October 30, 2023 Category: Neurology Source Type: research
Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease
This study compares the rates of atrial fibrillation detection through 3 years of follow-up between an insertable cardiac monitor vs site-specific usual care, in patients with prior ischemic stroke attributed to large-artery disease or small-vessel disease. (Source: JAMA Neurology)
Source: JAMA Neurology - October 30, 2023 Category: Neurology Source Type: research
Association Between Slow-Wave Sleep Loss and Incident Dementia
This cohort study examines data from a sample of participants in the Framingham Heart Study who completed 2 overnight polysomnography studies to assess whether reductions in slow-wave sleep are associated with the risk of incident dementia. (Source: JAMA Neurology)
Source: JAMA Neurology - October 30, 2023 Category: Neurology Source Type: research
Exploratory Tau Biomarker Results From a Study of BIIB080 in Alzheimer Disease
This randomized clinical trial examines data from patients with mild Alzheimer disease receiving BIIB080 to assess changes in tau biomarkers associated with cognitive decline, including cerebrospinal fluid total tau and phosphorylated tau 181 and tau positron emission tomography. (Source: JAMA Neurology)
Source: JAMA Neurology - October 30, 2023 Category: Neurology Source Type: research
Selfie-Induced Diagnostic Challenge in Horner Syndrome
This case report describes an 18-year-old woman with neurofibromatosis type 1 and prior right brachial plexus neurofibroma resection who reported intermittent, unilateral facial flushing after exertion. (Source: JAMA Neurology)
Source: JAMA Neurology - October 30, 2023 Category: Neurology Source Type: research
